@article {ref1,
	title = {Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid},
	journal = {Neurobiology of Aging},
	volume = {36},
	number = {10},
	year = {2015},
	month = {10/2015},
	pages = {2748-2756},
	publisher = {Elsevier},
	abstract = {<p>We here report synthesis for the first time of the acetyl salicylic acid dimer 5,5\&$\#$39;-methylenebis(2-acetoxybenzoic acid) (DAS). DAS inhibits aberrant complement activation by selectively blocking factor D of the alternative complement pathway and C9 of the membrane attack complex. We have previously identified aurin tricarboxylic and its oligomers as promising agents in this regard. DAS is much more potent, inhibiting erythrocyte hemolysis by complement-activated serum with an IC50 in the 100?170{\^A}?nanomolar range. There are numerous conditions where self-damage from the complement system has been implicated in the pathology, including such chronic degenerative diseases of aging as Alzheimer\&$\#$39;s disease, Parkinson\&$\#$39;s disease, amyotrophic lateral sclerosis, and age-related macular degeneration. Consequently, there is a high priority for the discovery and development of agents that can successfully treat such conditions. DAS holds considerable promise for being such an agent.</p>},
	doi = {10.1016/j.neurobiolaging.2015.06.018},
	url = {http://dx.doi.org/10.1016/j.neurobiolaging.2015.06.018},
	author = {Lee, Moonhee and Wathier, Matthew and Love, Jennifer A. and McGeer, Edith and McGeer, Patrick L.}
}
